Association Between ERα Gene Pvu II Polymorphism and Breast Cancer Susceptibility: A Meta-analysis

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2018 Apr 29

PMID 29702977

Citations 6

Authors

Zhen-Lian Zhang

Cui-Zhen Zhang

Yan Li

Zhen-Hui Zhao

Shun-E Yang

Affiliations

Soon will be listed here.

Abstract

Background: Estrogen has played an important role in the development of breast cancer. ER-α PvuII gene polymorphism is in close association with the occurrence risk of breast cancer, but no consensus has been achieved currently.

Methods: PubMed, Embase, China National Knowledge Infrastructure (CNKI) database, Wanfang database, and VIP database were retrieved to collect the case-control studies on association between ERα gene Pvu II polymorphism and breast cancer risk published before September 1, 2017. Newcastle-Ottawa Scale (NOS) was used to assess the quality of the literatures, Stata 14.0 software was applied for meta-analysis, and the pooled odds ratio (OR) and 95% confidence interval (95% CI) were calculated. The subgroup analysis was performed to assess the confounding factors, followed by assessment of publication bias and sensitivity analysis.

Results: A total of 26 studies were enrolled in the analysis based on inclusion criteria, which included 15,360 patients and 26,423 controls. The results demonstrated that ERα gene Pvu II polymorphism was in significant association with the decrease of breast cancer risk in 3 genetic models (C vs T, OR = 0.962, 95% CI = 0.933-0.992, P = .012; CC vs TT, OR = 0.911, 95% CI = 0.856-0.969, P = .003; CC vs TT/CT, OR = 0.923, 95% CI = 0.874-0.975, P = .004). Subgroup analysis was conducted on the basis of ethnicity and source of controls, whose results illustrated that ERα gene Pvu II polymorphism was in significant association with the decrease of breast cancer risk in Asians rather than in Caucasians (CC vs TT, OR = 0.862, 95% CI = 0.750-0.922, P = .038; CC vs TT/CT, OR = 0.851, 95% CI = 0.755-0.959, P = .008). In population-based subgroup rather than in hospital-based subgroup, ERα gene Pvu II polymorphism was in significant association with the decrease of breast cancer risk in the allele model, homozygous model, dominant model, and recessive model (C vs T, OR = 0.943, 95% CI = 0.911-0.977, P = .001; CC vs TT, OR = 0.878, 95% CI = 0.817-0.944, P = .000; CC/CT vs TT, OR = 0.936, 95% CI = 0.881-0.994, P = .031; CC vs TT/CT, OR = 0.902, 95% CI = 0.847-0.960, P = .001).

Conclusion: ERα gene Pvu II polymorphism exerts an important function in the progression of breast cancer.

Citing Articles

Analysis of Single Nucleotide Polymorphisms (SNPs) rs2234693 and rs9340799 of the Gene and the Risk of Breast Cancer.

Smolarz B, Nowak A, Brys M, Forma E, Lukasiewicz H, Samulak D In Vivo. 2024; 38(5):2134-2143.

PMID: 39187368 PMC: 11363788. DOI: 10.21873/invivo.13676.

Metabolic Syndrome, BMI, and Polymorphism of Estrogen Receptor-α in Peri- and Post-Menopausal Polish Women.

Krakowiak J, Raczkiewicz D, Humeniuk E, Wdowiak A, Wrobel A, Bojar I Metabolites. 2022; 12(8).

PMID: 35893240 PMC: 9330421. DOI: 10.3390/metabo12080673.

Association between gene polymorphisms and GPER expression levels with cancer predisposition and progression.

Ulhaq Z, Soraya G, Milliana A, Tse W Heliyon. 2021; 7(3):e06428.

PMID: 33748487 PMC: 7970143. DOI: 10.1016/j.heliyon.2021.e06428.

A Closer Look at Estrogen Receptor Mutations in Breast Cancer and Their Implications for Estrogen and Antiestrogen Responses.

Clusan L, Le Goff P, Flouriot G, Pakdel F Int J Mol Sci. 2021; 22(2).

PMID: 33451133 PMC: 7828590. DOI: 10.3390/ijms22020756.

Correlation of FGFR2 rs2981582 polymorphisms with susceptibility to breast cancer: a case-control study in a Chinese population.

Shu J, Hui X, Zheng X, Zhao J, Xu Z, Chen Y J Int Med Res. 2019; 47(10):4753-4763.

PMID: 31448667 PMC: 6833426. DOI: 10.1177/0300060519869058.

References

Gu Z, Wang G, Chen W . Estrogen receptor alpha gene polymorphisms and risk of prostate cancer: a meta-analysis involving 18 studies. Tumour Biol. 2014; 35(6):5921-30. DOI: 10.1007/s13277-014-1785-4. View

Mallepell S, Krust A, Chambon P, Brisken C . Paracrine signaling through the epithelial estrogen receptor alpha is required for proliferation and morphogenesis in the mammary gland. Proc Natl Acad Sci U S A. 2006; 103(7):2196-201. PMC: 1413744. DOI: 10.1073/pnas.0510974103. View

Lu X, Li B, Wei J, Hua B . [The XbaI and PvuII gene polymorphisms of the estrogen receptor alpha gene in Chinese women with breast cancer]. Zhonghua Wai Ke Za Zhi. 2005; 43(5):290-3. View

Zhang Y, Zhang M, Yuan X, Zhang Z, Zhang P, Chao H . Association Between ESR1 PvuII, XbaI, and P325P Polymorphisms and Breast Cancer Susceptibility: A Meta-Analysis. Med Sci Monit. 2015; 21:2986-96. PMC: 4599181. DOI: 10.12659/MSM.894010. View

McCormack V, Boffetta P . Today's lifestyles, tomorrow's cancers: trends in lifestyle risk factors for cancer in low- and middle-income countries. Ann Oncol. 2011; 22(11):2349-2357. DOI: 10.1093/annonc/mdq763. View

Wang J, Higuchi R, Modugno F, Li J, Umblas N, Lee J . Estrogen receptor alpha haplotypes and breast cancer risk in older Caucasian women. Breast Cancer Res Treat. 2007; 106(2):273-80. DOI: 10.1007/s10549-007-9497-8. View

Sonestedt E, Ivarsson M, Harlid S, Ericson U, Gullberg B, Carlson J . The protective association of high plasma enterolactone with breast cancer is reasonably robust in women with polymorphisms in the estrogen receptor alpha and beta genes. J Nutr. 2009; 139(5):993-1001. DOI: 10.3945/jn.108.101691. View

Atoum M, Alzoughool F . Reduction in breast cancer susceptibility due to gene polymorphism of alpha estrogen receptor gene in Jordanians. Breast Cancer (Dove Med Press). 2017; 9:45-49. PMC: 5279460. DOI: 10.2147/BCTT.S125652. View

Han J, Jiang T, Bai H, Gu H, Dong J, Ma H . Genetic variants of 6q25 and breast cancer susceptibility: a two-stage fine mapping study in a Chinese population. Breast Cancer Res Treat. 2011; 129(3):901-7. DOI: 10.1007/s10549-011-1527-x. View

10.

Herrington D, Howard T, Brosnihan K, McDonnell D, Li X, Hawkins G . Common estrogen receptor polymorphism augments effects of hormone replacement therapy on E-selectin but not C-reactive protein. Circulation. 2002; 105(16):1879-82. DOI: 10.1161/01.cir.0000016173.98826.88. View

11.

Li L, Xu L . Menopausal status modifies breast cancer risk associated with ESR1 PvuII and XbaI polymorphisms in Asian women: a HuGE review and meta-analysis. Asian Pac J Cancer Prev. 2012; 13(10):5105-11. DOI: 10.7314/apjcp.2012.13.10.5105. View

12.

Goldstein D, Weale M . Population genomics: linkage disequilibrium holds the key. Curr Biol. 2001; 11(14):R576-9. DOI: 10.1016/s0960-9822(01)00348-7. View

13.

Cai Q, Shu X, Jin F, Dai Q, Wen W, Cheng J . Genetic polymorphisms in the estrogen receptor alpha gene and risk of breast cancer: results from the Shanghai Breast Cancer Study. Cancer Epidemiol Biomarkers Prev. 2003; 12(9):853-9. View

14.

Shen Y, Li D, Wu J, Zhang Z, Gao E . Joint effects of the CYP1A1 MspI, ERalpha PvuII, and ERalpha XbaI polymorphisms on the risk of breast cancer: results from a population-based case-control study in Shanghai, China. Cancer Epidemiol Biomarkers Prev. 2006; 15(2):342-7. DOI: 10.1158/1055-9965.EPI-05-0485. View

15.

Surekha D, Vishnupriya S, Rao D, Sailaja K, Raghunadharao D . PvuII polymorphism of estrogen receptor-α gene in breast cancer. Indian J Hum Genet. 2011; 13(3):97-101. PMC: 3168145. DOI: 10.4103/0971-6866.38983. View

16.

Modugno F, Zmuda J, Potter D, Cai C, Ziv E, Cummings S . Association of estrogen receptor alpha polymorphisms with breast cancer risk in older Caucasian women. Int J Cancer. 2005; 116(6):984-91. DOI: 10.1002/ijc.21105. View

17.

Sun M, Du H, Zhu A, Liang H, Ruiz de Garibay G, Li F . Genetic polymorphisms in estrogen-related genes and the risk of breast cancer among Han Chinese women. Int J Mol Sci. 2015; 16(2):4121-35. PMC: 4346947. DOI: 10.3390/ijms16024121. View

18.

Gonzalez-Mancha R, Galan J, Crespo C, Iglesias Perez L, Gonzalez-Perez A, Jesus Moron F . Analysis of the ERalpha germline PvuII marker in breast cancer risk. Med Sci Monit. 2008; 14(3):CR136-43. View

19.

Kjaergaard A, Ellervik C, Tybjaerg-Hansen A, Axelsson C, Gronholdt M, Grande P . Estrogen receptor alpha polymorphism and risk of cardiovascular disease, cancer, and hip fracture: cross-sectional, cohort, and case-control studies and a meta-analysis. Circulation. 2007; 115(7):861-71. DOI: 10.1161/CIRCULATIONAHA.106.615567. View

20.

Cai L, Zhang J, Xue X, Wang Z, Wang J, Tang S . Meta-analysis of associations of IL1 receptor antagonist and estrogen receptor gene polymorphisms with systemic lupus erythematosus susceptibility. PLoS One. 2014; 9(10):e109712. PMC: 4186846. DOI: 10.1371/journal.pone.0109712. View